February 24-27, 2023, San Antonio, TX

American Academy of Allergy Asthma & Immunology (AAAAI)

February 25-28, 2022, Phoenix, AZ

American Academy of Allergy Asthma & Immunology (AAAAI)

American Academy of Allergy Asthma & Immunology (AAAAI)

thumb icon

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from the 52-week Phase 2b extension study

W. Carr, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, M. Wells, A. Zharkov, S. Hugot, A.M. Giménez-Arnau
Handout Oral presentation
thumb icon

Remibrutinib improves chronic spontaneous urticaria in patients irrespective of previous anti-Ige treatment: Results from a Phase 2b study

A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A.M. Giménez-Arnau, M. Maurer
Abstract Poster
thumb icon

Efficacy and safety of ligelizumab in chronic spontaneous urticaria: Results from the Phase-3 pivotal trials

L.F. Ensina, J.A. Bernstein, G. Sussman, M. Maurer, A.M. Giménez-Arnau, S. Saini, V. Varanasi, A. Barve, E. Hua, M. Patekar, T. Severin
Abstract Poster
thumb icon

Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline

K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin
Abstract Poster Poster slides
thumb icon

Ligelizumab improves dermatology quality of life in patients with chronic spontaneous urticaria regardless of angioedema status at baseline

W. Soong, J. A. Bernstein, K. Sitz, M. Maurer, A. M. Giménez-Arnau, C. E. Ortmann, T. Severin
Abstract Poster Poster slides
thumb icon

Ligelizumab for adolescent patients with CSU: First results from a dedicated Phase 2b study

M. Ben-Shoshan, B. E. Sekerel, P. Staubach, M. Alvaro-Lozano, M. Maurer, A. Drollmann,
A. Bienczak, M. Porter, T. Liu, A. Burciu, T. Severin
Abstract Poster Poster slides
thumb icon

Remibrutinib treatment improves quality of life in patients with chronic spontaneous urticaria

M. Maurer, A. M. Giménez-Arnau, V. Jain, J. Tillinghast, A. Tolcachier, S. Nigen,
K. Hayama, K. Lheritier, P. Walsh, S. Haemmerle
Abstract Poster Poster slides

2021

thumb icon

Ligelizumab is more effective in patients with chronic spontaneous urticaria previously treated with omalizumab

K. Sitz, G. Sussman, M. Metz, M. Hide, M. Maurer, N. Barbier, E. Hua, R. Janocha, T. Severin
Abstract Oral Presentation

2020

thumb icon

Long-term treatment with ligelizumab achieves prolonged symptom control during the post-treatment follow-up

W. Soong, JA. Bernstein, G. Sussman, B. Lanier, K. Sitz, M. Maurer, A. Giménez-Arnau, E. Hua, A. Barve, T. Severin, R. Janocha
Abstract Poster
AAAAI 2020 was postponed to 2021 and the presentations submitted to the congress were published. The virtual meeting conducted in 2020 included recordings of selected sessions.

2018 and 2019

No publication submitted this year

Novartis logo
Cookie Settings
© Copyright 2023 Novartis Pharma AG